<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01148069</url>
  </required_header>
  <id_info>
    <org_study_id>ID RCB 2009-A01336-51</org_study_id>
    <secondary_id>LOC/09-07</secondary_id>
    <secondary_id>CIC0203/128</secondary_id>
    <nct_id>NCT01148069</nct_id>
  </id_info>
  <brief_title>Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers</brief_title>
  <acronym>TARGET</acronym>
  <official_title>Surgery Combined With IMRT-IGRT in Locally-advanced Prostate Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard treatment of locally-advanced prostate cancers consists in the association of&#xD;
      radiotherapy of prostate and seminal vesicles (SV) and androgen deprivation (AD) for 3 years.&#xD;
      This treatment is usually preceded by pelvic lymphadenectomy to assess the possible extension&#xD;
      to lymph nodes of prostatic cancer and to avoid irradiating the pelvis in case of no lymph&#xD;
      node involvement. However, radiotherapy leads usually to about 30% of grade ≥2 risk of&#xD;
      bladder and/or rectal toxicity. This risk particularly depends on the radiation volume. In&#xD;
      the aim of lowering the toxicity, the treatment in this study will associate:&#xD;
&#xD;
        -  pelvic lymph node dissection and resection of seminal vesicles, allowing decreasing the&#xD;
           radiation target volume to the prostate only (and not to irradiate the SV);&#xD;
&#xD;
        -  a high-precision radiotherapy technique combining Intensity Modulated Radiation Therapy&#xD;
           (IMRT) and Image-Guided Radiation Therapy (IGRT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study targets non metastatic prostatic locally-advanced adenocarcinomas which are at&#xD;
      high risk of both local progression and metastases. The standard treatment of these tumours&#xD;
      associates external beam radiation therapy (EBRT) and 3 years of androgen deprivation (AD)&#xD;
      with LH-RH analogue. In the absence of AD and mainly when prostate specific antigen (PSA) is&#xD;
      &gt;10 ng/ml, several randomized studies have shown that high doses of EBRT increase biochemical&#xD;
      control. Nevertheless, escalating the doses of radiation significantly increases the risk of&#xD;
      rectal and/or urinary toxicities. In order to lower the toxicity of irradiation in&#xD;
      locally-advanced prostate cancers, and to improve the quality of life of patients, this study&#xD;
      aims at decreasing the volume of irradiated healthy tissues. To carry out this objective, we&#xD;
      will use a double strategy:&#xD;
&#xD;
        -  Limiting the target volume to prostate only by removing seminal vesicles at the time of&#xD;
           lymph node dissection,&#xD;
&#xD;
        -  Using a technique of high-precision radiation combining Intensity Modulated Radiation&#xD;
           Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT).&#xD;
&#xD;
      Based on the literature, we may assume a toxicity rate of 30% during the three years of&#xD;
      hormonotherapy with standard treatment (i.e. without removing seminal vesicles). We make the&#xD;
      hypothesis of a 20% absolute reduction of toxicity with our protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2010</start_date>
  <completion_date type="Actual">July 4, 2018</completion_date>
  <primary_completion_date type="Actual">July 4, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of bladder and/or rectal grade ≥2 toxicity (late toxicity)</measure>
    <time_frame>between 6 months and 3 years</time_frame>
    <description>Rate of bladder and/or rectal grade ≥2 toxicity (CTCAE V4.0) observed between 6 months and 3 years after the beginning of the radiotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose received by the rectum and the bladder with and without seminal vesicles irradiation</measure>
    <time_frame>Before treatment</time_frame>
    <description>Assessed using a dose-volume histogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed with EORTC questionnaires (QLQ-C30, QLQ-PR25)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile troubles</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed with erectile troubles questionnaire (IIEF-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of biological signs evocating a recidive</measure>
    <time_frame>3 years</time_frame>
    <description>Assessed with PSA levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of clinical signs evocating a recidive</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific and global survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bladder and/or rectal grade ≥2 toxicity (CTCAE V4.0) (early toxicity)</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of late bladder and/or rectal grade ≥2 toxicity (CTCAE V4.0) observed 6 months after the beginning of the radiotherapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Surgery combined with IMRT-IGRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery combined with IMRT-IGRT</intervention_name>
    <description>Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.</description>
    <arm_group_label>Surgery combined with IMRT-IGRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18,&#xD;
&#xD;
          -  Prostate adenocarcinoma (histologically proven),&#xD;
&#xD;
          -  Locally-advanced (T3a or Gleason &gt; 7 or PSA ≥ 20 ng/mL),&#xD;
&#xD;
          -  Distal half of seminal vesicles unaffected on MRI,&#xD;
&#xD;
          -  Non metastatic cancer: negative extension assessment (on prostatic and pelvic MRI and&#xD;
             bone scintigraphy),&#xD;
&#xD;
          -  Radiotherapy and hormonotherapy indication,&#xD;
&#xD;
          -  Medical insurance affiliation,&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Non-inclusion criteria:&#xD;
&#xD;
          -  Co-morbidity or medical history contraindicating surgery (pelvic lymphadenectomy and&#xD;
             seminal vesicle ablation),&#xD;
&#xD;
          -  Contraindication to pelvic irradiation,&#xD;
&#xD;
          -  Hip prosthesis,&#xD;
&#xD;
          -  History of cancer for the last 5 years (except baso-cellular epithelioma),&#xD;
&#xD;
          -  History of pelvic irradiation,&#xD;
&#xD;
          -  Person deprived of freedom or under guardianship,&#xD;
&#xD;
          -  Participation in another biomedical research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Surgery showing lymph nodes involvement (pelvic radiation indication)&#xD;
&#xD;
          -  Surgery without ablation of seminal vesicles&#xD;
&#xD;
          -  Surgery with positive margins in seminal vesicles&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud DE CREVOISIER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes CRLCC Eugène Marquis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastien VINCENDEAU, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric BELLISSANT, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Urologie - Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis - CRLCC</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 18, 2010</study_first_submitted>
  <study_first_submitted_qc>June 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>December 18, 2018</last_update_submitted>
  <last_update_submitted_qc>December 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMRT-IGRT</keyword>
  <keyword>radiotherapy toxicity</keyword>
  <keyword>seminal vesicles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

